

RESULT 8

AAR28869

ID AAR28869 standard; peptide; 31 AA.

XX

AC AAR28869;

XX

DT 25-MAR-2003 (revised)

DT 23-MAR-1993 (first entry)

XX

DE High affinity macrophage mannose receptor ligand compound #7.

XX

KW glycopeptide; mannose; mannosylated; glycosylated; mannose receptor;

KW macrophages; monocytes; destroy; cytotoxicity; label; image; alter;

KW macrophage processing of antigen; MHC restriction; inflammation;

KW inflammatory diseases; macrophage secretory products; Crohn's disease;

KW legionnaires disease; mononuclear phagocytes; HIV; AIDS;

KW lysosomal storage diseases; Gaucher's disease; asthma;

KW alveolar macrophages metastasis; systemic macrophages; deliver;

KW antigenic peptides; prevent transplant rejection; organ transplantation;

KW antitumour agents; cancer; toxins.

XX

OS Synthetic.

XX

FH Key Location/Qualifiers

FT Modified-site 1

FT /note= "opt may have mannose, fucose, glucose or N-Ac-

FT glucosamine. May also have non interfering substits."

FT Modified-site 3

FT /note= "opt may have mannose, fucose, glucose or N-Ac-

FT glucosamine. "

FT Modified-site 5

FT /note= "opt may have mannose, fucose, glucose or N-Ac-

FT glucosamine. "

FT Modified-site 7

FT /note= "opt may have mannose, fucose, glucose or N-Ac-

FT glucosamine. "

FT Modified-site 9

FT /note= "opt may have mannose, fucose, glucose or N-Ac-

FT glucosamine. "

FT Modified-site 11

FT /note= "opt may have mannose, fucose, glucose or N-Ac-

FT glucosamine. "

FT Modified-site 13

FT /note= "opt may have mannose, fucose, glucose or N-Ac-

FT glucosamine. "

FT Modified-site 15
FT /note= "opt may have mannose, fucose, glucose or N-Ac-
FT glucosamine. "
FT Modified-site 17
FT /note= "opt may have mannose, fucose, glucose or N-Ac-
FT glucosamine. "
FT Modified-site 19
FT /note= "opt may have mannose, fucose, glucose or N-Ac-
FT glucosamine. "
FT Modified-site 21
FT /note= "opt may have mannose, fucose, glucose or N-Ac-
FT glucosamine. "
FT Modified-site 23
FT /note= "opt may have mannose, fucose, glucose or N-Ac-
FT glucosamine. "
FT Modified-site 25
FT /note= "opt may have mannose, fucose, glucose or N-Ac-
FT glucosamine. "
FT Modified-site 27
FT /note= "opt may have mannose, fucose, glucose or N-Ac-
FT glucosamine. "
FT Modified-site 29
FT /note= "opt may have mannose, fucose, glucose or N-Ac-
FT glucosamine. "
FT Modified-site 31
FT /note= "opt may have mannose, fucose, glucose or N-Ac-
FT glucosamine. May also have non interfering substits."
XX
PN WO9219248-A1.
XX
PD 12-NOV-1992.
XX
PF 01-MAY-1992; 92WO-US003609.
XX
PR 03-MAY-1991; 91US-00694983.
XX
PA (UNIW) UNIV WASHINGTON.
XX
PI Stahl PD;
XX
DR WPI; 1992-398516/48.
XX
PT New high affinity mannose receptor ligand cpds. - for treating diseases
PT mediated by macrophage activity e.g. asthma, inflammatory diseases and
PT infectious diseases, e.g. HIV.
XX

PS Claim 3; Page 21; 32pp; English.

XX

This compound represents a glycopeptide effective in inhibiting the binding of labelled mannosylated BSA to mannose receptors. Mannose receptors are uniquely found on macrophages and not on monocytes. Glycopeptides such as this provide a mechanism to target macrophages specifically, to image, label, destroy or otherwise alter their antigen processing function. In addition they can be conjugated to solid supports and used to purify mannose receptors from a variety of sources. They are useful in the treatment of inflammatory diseases driven by macrophage secretory products eg. Crohn's disease; infectious diseases in which macrophages harbour replicating infectious agents eg. Legionnaires disease; viral infections involving mononuclear phagocytes eg. HIV and lysosomal storage diseases, in which macrophages are principally involved eg. Gaucher's disease; asthma mediated by alveolar macrophages; and in controlling metastasis, mediated by systemic macrophages. The peptides can also be used to deliver antigenic peptides as conjugates to a macrophage to marshal an immune response; also self peptides to prevent tissue transplant rejection. (Updated on 25-MAR-2003 to correct PN field.)

XX

SQ Sequence 31 AA;

Query Match 6.3%; Score 18; DB 2; Length 31;

Best Local Similarity 100.0%; Pred. No. 3.1e-09;

Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 97 KPKPKPKPKPKPKPKP 114

|||||

Db 1 KPKPKPKPKPKPKPKP 18